203187-18-2

Upstream product

• 157338-47-1 1-(trifluoroacetyl)-4-benzylpiperidine 
• 331765-80-1 1-[4-(4-bromobenzyl)piperidin-1-yl]-2,2,2-trifluoroethanone 

Downstream Products

• 203187-19-3 4-(4-bromo-benzyl)-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 1258290-89-9 ethyl 2-{4-(4-bromobenzyl)piperidin-1-yl}acetate 
• 1200130-90-0 4-(4-bromobenzyl)-1-methylpiperidine 

Relevant academic research and scientific papers

MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE

Provided are methods for delaying or preventing onset of progressive memory decline by administering a muscarinic M2 receptor blocking compound to patients identified as at risk of developing a condition characterized by progressive memory decline, prior

SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine c

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists

Bipiperidine amide 1 has been identified as a CC chemokine receptor 3 (CCR3) antagonist. Optimization of its structure-activity relationship has resulted in the identification of cis (R,R)-4-[(3,4-dichlorophenyl)methyl]-3- hydroxymethyl-1′(6-quinolinylcar

Isopropyl amide derivatives of potent and selective muscarinic M 2 receptor antagonists

Low molecular weight amide derivatives were synthesized and evaluated as M2 receptor antagonists for the treatment of Alzheimer's disease. Isopropyl amides 19 and 31 are highly potent, selective and low molecular weight M2 receptor a

Muscarinic M2 antagonists: Anthranilamide derivatives with exceptional selectivity and in vivo activity

Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.

MUSCARINIC ANTAGONISTS

Amide derivatives of 1,4 di-substituted piperidine compounds of formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein Q and Q are each -CH=, or one of Q and Q is -CH= and the other is -N=; X is -CH2- or (a); Y and Z are -C(R)=, or one of Y and Z is -C(R)= and the other is -N=; R is 1 to 3 substituents selected from H, halogen and alkoxy; R and R are 1 to 3 substituents selected from H, halogen, alkyl and alkoxy; and R and R are H or (C1-C6) alkyl are muscarinic antagonists usuful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed.